EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CKD progression, kidney failure, and mortality among US patients with IgA nephropathy

John J Sim iD, Qiaoling Chen, Nancy Cannizzaro, Ancilla W Fernandes, Cibele Pinto, Simran K Bhandari, John Chang, Asher D Schachter, Mohit Mathur

Nephrology Dialysis Transplantation · 30.10.2025 · 40 (11) · 2104-2117

DOI: 10.1093/ndt/gfaf084 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 30.04.2025. Verfasst von John J Sim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology and Hypertension, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, USA. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Renal Insufficiency, Chronic, Renal Insufficiency, Kidney Failure, Chronic. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Otsuka Pharmaceutical Development and Commercialization.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Hypothesis We assessed disease progression among patients with immunoglobulin A nephropathy (IgAN) and characterized factors associated with risk for adverse outcomes.

Methods

A retrospective longitudinal cohort (2000–2022) study of adults with biopsy-confirmed IgAN within Kaiser Permanente Southern California was performed. The outcome of interest was a composite of ≥50% estimated glomerular filtration rate (eGFR) decline, kidney failure, or mortality. Cox proportional hazards regression modeling was used to estimate hazard ratios (HR) for the eGFR decline/kidney failure with adjustment for potential confounders.

Results

Among 655 patients with primary IgAN (31% Asian/Pacific Islander, 3% Black, 40% Hispanic/Latino, 24% White), 234 (36%) reached the composite outcome of ≥50% eGFR decline (17%), kidney failure (16%), or mortality (3%). The composite outcome occurred at a rate of 79.4 events (95% confidence intervals (CI) 69.6, 90.7) per 1000 patient-years, with a median time to event of 2.7 years. Compared to urine protein creatinine ratio (UPCR) <0.5 vs 0.5–<1 g/g, 1–2, and >2 g/g, the HR (95% CI) for ≥50% eGFR decline/kidney failure were 2.4 (1.1, 5.1), 3.2 (1.5, 6.6), and 5.1 (2.5, 10.4) for baseline UPCR and 5.4 (2.3, 13.0), 14.4 (16.5, 32.2), and 41.2 (17.9, 94.5) for time-averaged UPCR. Lower baseline eGFR and diabetes were also associated with higher risk, while age ≥30 years was associated with lower risk for ≥50% eGFR decline/kidney failure. There were no clear trends differentiating risk by race/ethnicity.

Conclusion

In this large, diverse cohort, high rates of kidney outcomes occurred within a relatively short follow-up duration. Our findings suggest that IgAN carries elevated risk for kidney outcomes starting at proteinuria levels ≥0.5 g/g, in contrast to earlier perceptions that levels below 1 g/g are associated with low risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, IGARenal Insufficiency, ChronicRenal InsufficiencyKidney Failure, ChronicHumansMaleFemaleDisease ProgressionRetrospective StudiesGlomerular Filtration RateAdultMiddle AgedFollow-Up StudiesPrognosisLongitudinal StudiesRisk FactorsSurvival RateUnited States

Stichwörter der Autor:innen

IgANepidemiologyimmunoglobulin A nephropathykidney failure

Autor:innen und Institutionen

  • Department of Nephrology and Hypertension, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, USA.
  • Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
  • Department of Clinical Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA.
  • Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ, USA.
  • Department of Internal Medicine, Kaiser Permanente Downey Medical Center, Downey, CA, USA.
  • Visterra, Inc., Waltham, MA, USA.

ORCID-Profile: John J Sim

Förderung

  • Otsuka Pharmaceutical Development and Commercialization

Zitieren

APA

Sim, J. J., Chen, Q., Cannizzaro, N., Fernandes, A. W., Pinto, C., Bhandari, S. K., Chang, J., Schachter, A. D., & Mathur, M. (2025). CKD progression, kidney failure, and mortality among US patients with IgA nephropathy. Nephrology Dialysis Transplantation, 40(11), 2104-2117. https://doi.org/10.1093/ndt/gfaf084

Vancouver

Sim JJ, Chen Q, Cannizzaro N, Fernandes AW, Pinto C, Bhandari SK, et al. CKD progression, kidney failure, and mortality among US patients with IgA nephropathy. Nephrology Dialysis Transplantation. 2025;40(11):2104-2117. doi:10.1093/ndt/gfaf084

BibTeX
@article{Sim2025,
  author = {Sim, John J and Chen, Qiaoling and Cannizzaro, Nancy and Fernandes, Ancilla W and Pinto, Cibele and Bhandari, Simran K and Chang, John and Schachter, Asher D and Mathur, Mohit},
  title = {CKD progression, kidney failure, and mortality among US patients with IgA nephropathy},
  journal = {Nephrology Dialysis Transplantation},
  year = {2025},
  volume = {40},
  number = {11},
  pages = {2104--2117},
  doi = {10.1093/ndt/gfaf084}
}
Kostenlos starten →